Stay up-to-date on the latest news and information from UCB, 2007 - 2022UCB S.A., Belgium. All rights reservedLast updated on:April, 07, 2022, Syndesi Therapeutics is based in Belgium and will leverage UCBs neurology expertise in modulating the synaptic vesicle protein SV2A. About UCB Ventures. The companys drugs are small molecules that modulate synaptic transmission, which is the communication that happens between neurons in the brain. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. 2022 Breaking Media, Inc. All rights reserved. Tick the boxes of the newsletters you would like to receive. . Dispersion and Wet Milling Technology for Pharmaceuticals, Supply Chain Support Services for Life Science Companies, Thank you for subscribing to Pharmaceutical Technology, The leading site for news and procurement in the pharmaceutical industry, Receive our newsletter - data, insights and analysis delivered to you. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. AbbVie R&D senior vice-president and chief scientific officer Tom Hudson said: There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases. You need JavaScript enabled to view it. Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. It also presents a list of recommendations for addressing these challenges. Driven by science. V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre dEntreprises et dInnovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. Bone Therapeutics is a bone cell therapy company specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa; August 26 2022 | News No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak; August 24 2022 | News Appointments and advancements for Aug. 24, 2022; August 24 2022 | Press Releases In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the worlds premier life science institutes. Pipeline Prospector delivers free access to a database of Neurology drugs under clinical trials which made headlines done by Syndesi Therapeutics Milestone payments could bring shareholders of the biotech up to $870 million more. Regulating the synaptic transmission is a promising approach to treat Alzheimer's disease and other disorders with cognitive impairment. Fountains main office is in Dublin, Ireland, with a second office in New York. Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2021 was worth almost DKK 700 billion Danish Kroner (approximately US$93.73 billion) and is the largest charitable foundation in the world making Novo . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. ABOUT HD; ABOUT ALS; NEWS. Established in 2017, Syndesi focuses on developing new treatments that regulate synaptic activity to alleviate cognitive impairment symptoms. //-->. Company Presentation . Its current portfolio fair value is above 150 million . var addy45869 = 'info' + '@'; READ MORE ABOUT US. Obsidian Therapeutics is using its proprietary cytoDRiVE platform to harness the power of proteins to engineer precision medicines. Their latest funding was raised on Sep 28, 2020 from a Series A round. var path = 'hr' + 'ef' + '='; Presently in Phase Ib clinical trials, SDI-118 is being analysed for its potential ability to boost synaptic efficiency by acting on nerve terminals. flanders.bio wants to improve your user experience on this website. About Syndesi Therapeutics Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre d'Entreprises et d'Innovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. AbbVies portfolio and pipeline is thin on brain drugs, particularly in the area of neurodegeneration. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio. Unlike, UCB is the world leader in SV2A research, having discovered and developed two major anti-epileptic drugs treating patients around the world. Back to companies The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. A weekly roundup of the latest news and analysis, sent every Friday. Prilenia Therapeutics. AbbVies neuroscience drug prospects are from its partnership with Calico Life Sciences, a firm founded by Google parent company Alphabet. About Syndesi Therapeutics. The AbbVie/Calico alliance, started in 2014, has advanced three programs to clinical testing in neurodegeneration and cancer. Synaptic dysfunction, with the consequent disruption of connectivity bet ween brain regions, underlies cognitive impairment seen in multiple CNS . Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". All rights reserved. UCB has already developed and commercialized two products that address this target, the epilepsy drugs Keppra and Briviact. The Company's approach is aimed at treating Alzheimer's Disease and other disorders with cognitive impairment. LEARN MORE For more information about AbbVie, please visit us atwww.abbvie.com. Clinical trial records show the drug is currently in two Phase 1b tests, one enrolling elderly patients with cognitive decline and the other testing the drug candidate in adults in remission from depression. UCBs Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Lead Syndesi drug candidate SDI-118 came from UCB research of molecules that regulate SV2A, but to improve cognition rather than stop epileptic seizures. addy45869 = addy45869 + 'lamerie' + '.' + 'com'; Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its lead compound SDI-118, supporting further development of this promising molecule. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundations assets. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. WHO WE ARE . UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders, 2007 - 2022UCB S.A., Belgium. Ferrous(II) glycine sulphate complex (Ferro Sanol), Plain language summaries of study results, Access to Patient-Level Clinical Study Data, Plain Language Summaries of research results, Registration and Results Reporting on Public Registries, Cimzia - Axial spondyloarthritis (axSpA), Privacy Policy for Healthcare Professionals, Syndesi Therapeutics to leverage UCBs expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism, Series A financing of 17 M from a syndicate of Belgian and international investors. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. "I am delighted with the closing of this deal. Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Last year, the alliance was extended for a second time to continue clinical development of the partnered projects. Innovative Med Concepts USA Private Innovative Med Concepts is a biotech company with a pipeline of novel treatments for fibromyalgia and other related . SV2A plays a central role in synaptic transmission (connections between neurons). Blame the Middlemen, Survey: While Only Half of Americans Have Heard of Virtual Primary Care, Satisfaction Is High, Gynecological Health Startup Eyes US Launch with $11.5M in Series A Funding, Humana finds formula for senior-focused care, Inflations impact on healthcare switchboards and call centers, Improving the patient experience one call at a time, How to navigate the challenges of working with low-code platforms. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. The mechanism is currently being evaluated . Tom Hudson, senior vice president, R&D, and chief scientific officer of AbbVie, said that his company plans to evaluate the Syndesi molecule in a range of brain disorders. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. IMPROVING THE LIVES OF PATIENTS AND THEIR FAMILIES. document.getElementById('cloak45869').innerHTML = ''; UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. Copenhagen, Denmark - Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi') has been acquired by AbbVie (NYSE: ABBV) for up to US$1 billion in total deal value with US$ 130 million upfront. In 2017, the Belgian pharmaceutical company established a partnership with an investor group that included Novo Holdings, Fountain Healthcare Partners, and Johnson & Johnson InnovationJJDC. Type Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics The Belgian life science ecosystem is particularly vibrant and we realised that it was the right environment to promote this research as part of our biotech model approach., Jonathan Savidge, PhD CEO of Syndesi noted Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimers Disease and other indications characterized by cognitive impairment. Syndesi Therapeutics is developing molecules that modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Syndesi Therapeutics is funded by 9 investors. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors. Macrophage Therapeutics has developed a proprietary targeted steroid (MT-2000 class) designed to specifically treat the disease-causing cells quarterbacking the body's inflammatory response (Macrophages). Syndesi benefits both from UCBs research expertise and from an impressive syndicate of experienced investors and their respective networks., Cognitive impairment remains an area of significant unmet need for patients not only with Alzheimers Disease but also more broadly across a range of neurological disorders, and we are excited about the potential promise of this novel therapeutic approach, says Morten Graugaard Dssing, Principal at Novo Seeds. //